TriPath expands VIAS menu
This article was originally published in The Gray Sheet
VIAS (Ventana Image Analysis System) can now be used to measure levels of tumor suppressor biomarker p53 in breast biopsy samples, with 510(k) clearance announced Oct. 12. High expression of the p53 protein has been linked to more aggressive breast cancers, and precise quantification can aid pathologists in forming a diagnosis and planning the appropriate course of treatment, TriPath Imaging says. The VIAS system, distributed by Ventana Medical Systems, also is cleared for estrogen and progesterone receptor applications, as well as Ki-67 and HER-2/neu assays (1"The Gray Sheet" June 13, 2005, p. 24)...
You may also be interested in...
TriPath Imaging's launch of two diagnostic products in May helped drive a 33.8% increase in the firm's stock price to $8.59
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.